Flutiform recommended for approval in Japan

1 August 2013

UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical Affairs and Food Sanitation Council’s Second Committee on Drugs, of the Japanese Ministry of Health, Labour and Welfare (MHLW), has recommended approval of Flutiform (a fixed dose formulation of fluticasone and formoterol) for bronchial asthma treatment in Japan.

Flutiform is licensed to Kyorin Pharmaceutical (TYO: 4569) for Japan. A milestone of several million US dollars is payable to Skyepharma on approval of Flutiform in Japan. Skyepharma will also receive high-mid single digit royalties on net sales.

MHLW will now consider final approval and pricing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK